SSTR-2作为荧光引导脑膜瘤手术的潜在肿瘤特异性标志物
该研究对148例涵盖所有WHO级别的脑膜瘤标本进行组织芯片免疫组化,检测EMA、PDGF-β、VEGF-α和SSTR-2的表达,并按TASC标准筛选最佳靶点。SSTR-2染色最强,全部病例阳性,TASC总分21分(满分22),被认为是最有希望的荧光引导成像靶点;3D培养中3例有2例确认SSTR-2细胞膜表达。
要点
- 148例脑膜瘤组织芯片免疫组化中SSTR-2染色最强,全部病例阳性。
- SSTR-2染色51.4%为强/弥漫型,30.4%为中等/弥漫型,18.2%为局灶/弱型。
- TASC分析SSTR-2总分21分(满分22),为最有希望的靶向受体。
核心结论
- SSTR-2在全部148例脑膜瘤中表达具有高敏感性和特异性,且与WHO级别无关;按TASC分析,SSTR-2是脑膜瘤靶向最有希望的受体。
- 在3D脑膜瘤培养模型中,3例已建立培养中有2例确认SSTR-2细胞膜表达,提示可在实验条件下进行特异性荧光成像,以进一步开发靶向荧光引导脑膜瘤手术及靶向SSTR-2的近红外荧光示踪剂。
研究设计与样本
- 对148例涵盖所有脑膜瘤级别的脑膜瘤标本,采用组织芯片(TMA)免疫组化(IHC)检测EMA、PDGF-β、VEGF-α和SSTR-2的表达模式。
- 依据TArget Selection Criteria(TASC)筛选最有希望的标志物,并在由新鲜切除肿瘤材料生成的3D细胞培养模型中以IHC检查标志物表达。
主要发现
- TMA-IHC显示SSTR-2染色最强,全部病例阳性,其中51.4%为强/弥漫染色,30.4%为中等/弥漫染色,仅18.2%为局灶/弱染色。
- 所有检测的标志物在所有脑膜瘤中均至少呈弱阳性,与WHO级别无关。
- TASC分析显示SSTR-2为荧光引导成像最有希望的靶点,总分21分(满分22)。
- SSTR-2表达在原始患者肿瘤及三例已建立培养的3D培养物中进行了检测。
关键数值与推荐
- SSTR-2 TASC总分为21分(满分22分)。
- 148例脑膜瘤SSTR-2免疫组化染色分布:强/弥漫51.4%,中等/弥漫30.4%,局灶/弱18.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas are the most frequently occurring primary intracranial tumours in adults. Surgical removal can only be curative by complete resection; however surgical access can be challenging due to anatomical localization and local invasion of bone and soft tissues. Several intraoperative techniques have been tried to improve surgical resection, including intraoperative fluorescence guided imaging; however, no meningioma-specific (fluorescent) targeting has been developed yet. Here, we aimed to identify the most promising biomarkers for targeted intra-operative fluorescence guided meningioma surgery. METHODS: One hundred forty-eight meningioma specimens representing all meningioma grades were analysed using immunohistochemistry (IHC) on tissue microarrays (TMAs) to determine expression patterns of meningioma biomarkers epithelial membrane antigen (EMA), platelet-derived growth factor β (PDGF-β), vascular endothelial growth factor α (VEGF-α), and somatostatin receptor type 2 (SSTR-2). Subsequently, the most promising biomarker was selected based on TArget Selection Criteria (TASC). Marker expression was examined by IHC in 3D cell culture models generated from freshly resected tumour material. RESULTS: TMA-IHC showed strongest staining for SSTR-2. All cases were positive, with 51.4% strong/diffuse, 30.4% moderate/diffuse and only 18.2% focal/weak staining patterns. All tested biomarkers showed at least weak positivity in all meningiomas, regardless of WHO grade. TASC analysis showed that SSTR-2 was the most promising target for fluorescence guided imaging, with a total score of 21 (out of 22). SSTR-2 expression was determined on original patient tumours and 3D cultures of three established cultures. CONCLUSIONS: SSTR-2 expression was highly sensitive and specific in all 148 meningiomas, regardless of WHO grade. According to TASC analysis, SSTR-2 is the most promising receptor for meningioma targeting. After establishing in vitro meningioma models, SSTR-2 cell membrane expression was confirmed in two of three meningioma cultures as well. This indicates that specific fluorescence in an experimental setting can be performed for the further development of targeted fluorescence guided meningioma surgery and near-infrared fluorescent tracers targeting SSTR-2.
引用
- Dijkstra BM, Motekallemi A, den Dunnen WFA, et al. SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery. Acta Neurochir (Wien). 2018. PMID: 29858948. doi:10.1007/s00701-018-3575-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。